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Levosimendan in Critical Illness: A Literature Review
Charalampos Pierrakosa, Dimitrios Velissarisb, Federico Franchic, Luigi Muzzic,
Menelaos Karanikolasd, e, Sabino Scollettac

Abstract
Levosimendan, the active enantiomer of simendan, is a calcium
sensitizer developed for treatment of decompensated heart failure,
exerts its effects independently of the beta adrenergic receptor and
seems beneficial in cases of severe, intractable heart failure. Levosimendan is usually administered as 24-h infusion, with or without
a loading dose, but dosing needs adjustment in patients with severe liver or renal dysfunction. Despite several promising reports,
the role of levosimendan in critical illness has not been thoroughly
evaluated. Available evidence suggests that levosimendan is a safe
treatment option in critically ill patients and may reduce mortality
from cardiac failure. However, data from well-designed randomized controlled trials in critically ill patients are needed to validate
or refute these preliminary conclusions. This literature review is an
attempt to synthesize available evidence on the role and possible
benefits of levosimendan in critically ill patients with severe heart
failure.
Keyword: Levosimendan; Heart failure; Intensive care; Critical
care; Renal failure; Liver failure; Heart failure; Sepsis; Myocardial
infarction; Shock; Cardiogenic shock; Septic shock; Diastolic dysfunction; Coronary artery surgery; Valve surgery

Introduction
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threatening manifestations of critical illness and are associated with high mortality [1]. Fluid administration serves
as first-line therapy, but is often insufficient to improve patient’s condition, whereas beta-adrenergic agents increase
cardiac output (CO) and organ perfusion through inotropic
and chronotropic effects. Dobutamine, a beta-adrenergic
agent commonly used in severe heart failure, increases CO,
but also increases myocardial oxygen consumption, thereby
increasing the risk of myocardial ischemia and ventricular
dysfunction. Consequently, there are significant concerns regarding the balance of benefit vs. harm with dobutamine use
in critically ill patients, and a recent systematic review suggests that dobutamine may increase mortality [2].
Levosimendan, the active enantiomer of simendan, is a
calcium sensitizer that was developed for treatment of decompensated heart failure (DHF). Unlike other inotropic
agents, levosimendan enhances myocardial contractility
without increasing myocardial oxygen consumption, and its
primary actions are independent of interactions with adrenergic receptors. Compared to beta-adrenergic agents, presumed advantages of levosimendan include its combined
inotropic and vasodilation (inodilator) effect, efficacy on patients receiving beta-blockers and minimal effects on heart
rate. Although levosimendan has been endorsed by the European Society of Cardiology for patients with acutely decompensated severe chronic heart failure [3], and a recent
meta-analysis showed that levosimendan reduces mortality
in critically ill patients [4], levosimendan is not widely used
in intensive care units (ICUs). The aim of this review is to
summarize and evaluate current evidence on the role of levosimendan in critically ill patients.

Levosimendan: Mechanism of Action
Levosimendan is a calcium sensitizer and exerts its inotropic
effect principally via binding to the Ca++ saturated troponin
C of myocardial thin filament. This action results in stabilization of the Ca-bound conformation of troponin, thereby
prolonging the actin-myosin interaction without altering
cross-bridge cycling [5]. Although levosimendan inhibits
phosphodiesterase III, its inotropic effect seems to depend
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almost entirely on its calcium sensitizing properties [6].
Consequently, in contrast to other inotropic agents, levosimendan does not increase calcium flux into the cell, and this
could explain why levosimendan does not worsen myocardial diastolic dysfunction, and may actually improve diastolic
function [7]. Interestingly, despite improved cardiac performance, levosimendan does not increase myocardial oxygen
consumption and may increase myocardial oxygen supply
through coronary vasodilation [8, 9].
Levosimendan causes vasodilation through its effect
on K+ channels: it opens the K+ channels causing smooth
muscle membrane hyperpolarization, thereby inhibiting calcium channels and promoting vasodilation [10]. However,
because the vasodilator effect of levosimendan is observed
at plasma concentrations higher than those needed for positive inotropic effects [11], its clinical significance is unclear.
Levosimendan also induces vasodilation in other organs,
including the myocardium, gastric mucosa [12], lungs [13],
small intestine, liver and renal medulla [14]. As a result, organ perfusion is improved despite a small reduction of mean
arterial pressure [9]. However, the clinical significance of
levosimendan-related vasodilation has not been evaluated in
critically ill patients, because studies evaluating levosimendan safety usually exclude patients with severe hypotension
(systolic blood pressure (SBP) < 90 mmHg) (Table 1). The
clinical consequences of levosimendan-related vasodilation
should be evaluated taking in consideration concurrent improvement in cardiac performance.
In addition to its inotropic and vasodilator effects, levosimendan has several other important effects, including antiinflammatory effect [15, 16] and anti-apoptotic effects [15].
Levosimendan decreases pro-inflammatory cytokine production by diminishing transforming growth factor (TGF)-beta3
and Smad1, Smad2 and Smad3 expression [17]. In addition,
simendans downregulate NF-kappaB-dependent transcription and decrease inducible NO synthase (iNOS) promoter
activity, iNOS expression and nitric oxide (NO) production
[18].

Pharmacokinetics
Studies in healthy volunteers show that levosimendan pharmacokinetics are linear to the dose: the area under the plasma concentration-time curve (AUC) increases linearly and
correlates with dose [19]. Levosimendan is 97-98% bound
to plasma protein (mainly albumin) [20], has a small volume of distribution and its elimination from plasma is fast,
with half-life being about 1 h [20]. Levosimendan is almost
entirely metabolized by the liver before being eliminated by
conjugation with glutathione, forming N-acetylated cysteine
or cysteine-glycine. N-acetylated cysteine is excreted via the
biliary route to the intestine, and is then eliminated by the
kidneys [21].
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A small amount of levosimendan is eliminated unchanged through diffusion in the intestine, where it is
transformed by intestinal bacteria to OR-1855 [22]. Then,
OR-1855 is absorbed and further acetylated by N-acetyltransferase (NAT2) to OR-1986, which has effects similar to
the parent substance [23] and half-life 60 - 80 h [24]. Nearly
50% of OR-1986 is eliminated unchanged into urine, and the
remainder is eliminated via other metabolic routes, including
conversion back to OR-1855 [25].
Based on pharmacokinetic properties, levosimendan kinetics are influenced by: 1) albumin levels, 2) gastrointestinal function and intestinal bacterial flora, 3) liver function, 4)
NAT2 activity and 5) renal function.
Levosimendan and albumin levels
Hypoalbuminemia [26] and gastrointestinal dysfunction [27]
are common in ICU patients, but their effects on levosimendan pharmacokinetics have not been studied. In a case report, low dose (0.07 µg/kg/min) levosimendan was effective
in a patient with hypoalbuminemia (albumin level 3.1 mg/
dL) [28]. In addition, two studies evaluating levosimendan
on patients with low albumin levels due to chronic renal or
liver failure showed that the mean unbound fraction of levosimendan did not differ compared to healthy people [29, 30].
However, albumin levels in these two studies were higher
(3.8 g/dL ± 0.1 and 3.9 g/dL ± 0.1, respectively) compared
to albumin levels commonly reported in critically ill ICU
patients.
Levosimendan and liver dysfunction
Liver dysfunction is common in ICU patients, and use of
standard liver function tests may not be sufficient for evaluating liver function [31]. One small prospective study comparing levosimendan pharmacokinetics in 12 patients with
Child-Pugh class B cirrhosis vs. 12 healthy subjects showed
that OR-1896 elimination time was longer in cirrhosis patients [29]; however, this study did not include critically ill
patients or patients with heart failure. Unfortunately, patients
with liver dysfunction were excluded from two multi-center
studies evaluating levosimendan safety [32, 33]; therefore
data on levosimendan safety in patients with liver disease are
very limited, and more work is needed in this area. Currently
available data on the safety of levosimendan in critically ill
patients are summarized in Table 1.
Levosimendan and renal dysfunction
Acute renal failure is common in critically ill patients, and
may affect the pharmacokinetics of levosimendan and its
metabolites (OR-1896), due to reduced excretion. Levosimendan is not eliminated by hemodialysis, but levosimendan
metabolites are dialyzable, yet clearance through dialysis is
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Table 1. Studies Evaluating the Safety of Levosimendan in Critically Ill Patients

Study

Dose bolus

Dose infusion

Duration

Major adverse effects

Aidonidis et al. Cardiol
Res Pract. 2011 [35]

0

0.05 - 0.2 µg/kg/min

72 h

No discontinuations due to
adverse effects, two patients
died of advanced heart
failure.

Follath et al. Lancet.
2002 [38]

24 µg/kg

0.1 µg/kg/min

24 h

Hypotension, headache,
hypokalemia

0.05 - 0.1 µg/kg/min

7 days

No major adverse effects, no
premature discontinuations

Kivikko et al. J Clin
Pharmacol. 2002 [37]
Moiseyev et al. Eur
Heart J. 2002 [32]

6, 12, 24 µg/kg

0.1 - 0.4 µg/kg/min

6h

Hypotension, myocardial
rupture, headache, sinus
tachycardia

Poelzl et al. Herz. 2008
[75]

6 - 12 µg/kg

0.07 - 0.2 µg/kg/min

24 h

Not reported

Silva-Cardoso et al. Rev
Port Cardiol. 2009 [33]

12 µg/kg

0.05 - 0.2 µg/kg/min

24 h

Hypotension, hypokalemia

very slow (approximately 100 mL/min), and therefore short
hemodialysis sessions may not have important effects [30].
An open label study on 12 patients with severe chronic renal
failure and 13 patients with end-stage renal disease (ESRD)
undergoing hemodialysis showed that, compared to healthy
individuals, plasma half-life of levosimendan metabolites is
prolonged by 50%, while the AUC and peak plasma concentrations are approximately twice as high in patients with
severe renal dysfunction and those requiring hemodialysis
[30]. However, we could not find studies evaluating levosimendan pharmacokinetics in patients with severe renal dysfunction in the setting of critical illness.
In conclusion, our literature review shows that levosimendan pharmacokinetics have not been well evaluated in
critically ill patients, therefore more studies are needed to
clarify this important issue.

Levosimendan Dose
A wide range of levosimendan doses has been reported in
critically ill patients (Table 1), with doses differing significantly between studies (bolus 0 - 24 µg/kg, continuous infusion 0.05 - 0.2 µg/kg/min) [4]. The hemodynamic effects of
levosimendan seem to be dose-dependent [23], but are also

influenced by severity of heart failure. A multi-center (35
centers) open label observational study in Brazil included
182 patients with DHF and left ventricular ejection fraction
(LVEF) < 35% and the primary end point was hospital discharge without need for inotropic support after levosimendan infusion. One hundred and thirty-nine of 182 patients
(76.4%) met the primary end point and were classified as
responders, and hospital mortality was 14.8% (27 patients).
In this study, 25 of 30 patients receiving beta-blockers responded well to levosimendan. In contrast, in the subset of
71 patients who had received beta-agonist inotropes for 48
h and had failed to improve, only 39 of 71 patients (56%)
responded, thereby suggesting that patients with more severe
heart dysfunction respond less favorably to levosimendan
[34].
Several studies have evaluated levosimendan safety in
patients with acute heart failure or decompensated chronic
heart failure. Two studies evaluated levosimendan safety,
with dose titrated based on tolerance and/or clinical effects
[33, 35]. The RUSSLAN study, a randomized controlled trial
(RCT) on 504 patients with left ventricular failure after acute
myocardial infarction (MI) evaluated different levosimendan
doses (bolus 6, 12 and 24 μg/kg, continuous infusion 0.1 0.2 μg/kg/h for 6 h) vs. placebo and showed higher frequency of hypotension and/or ischemia in the highest dose group,
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and significantly lower mortality in all levosimendan groups
compared to placebo [32]. Interestingly, these studies did not
report adverse effects after the bolus doses.
Most published studies evaluate levosimendan administration for 24 h and show rapid initial hemodynamic improvement that persists after levosimendan discontinuation
[36]. In addition, one prospective study on 70 patients with
decompensated chronic heart failure evaluated prolonged
(up to 72 h) levosimendan infusion without a loading dose
and showed significant reduction of brain natriuretic peptide
(BNP) levels at 48 h and 72 h without major complications
[35]. Similarly, a prospective non-randomized study on 24
patients with New York Heart Association (NYHA) III-IV
heart failure evaluated a 7-day levosimendan infusion at
0.05 μg/kg/min (12 patients) or 0.1 μg/kg/min (12 patients)
and showed that prolonged levosimendan infusion was well
tolerated without premature discontinuations, but adverse
effects included prolonged increase in heart rate and minor
decrease in blood pressure [37]. However, the benefits, if
any, of prolonged (> 24 h) levosimendan administration vs.
conventional 24 h infusions have not been evaluated.

Levosimendan vs. Other Inotropes
Levosimendan vs. dobutamine
Levosimendan was compared to dobutamine in a multi-center RCT (LIDO study) on 213 patients with low CO heart failure (acute or decompensated chronic heart failure) requiring
intravenous inotropes [38]. In this study, levosimendan was
more effective than dobutamine in producing hemodynamic improvement: more patients in the levosimendan group
(28% vs. 15%; P = 0.02) had CO increase by at least 30%
and pulmonary-capillary wedge pressure decrease by 25%
compared to baseline at 24 h. It is possible that levosimendan is more effective than dobutamine because it improves
left ventricular diastolic function parallel with improvement
of systolic function [39]. In general, levosimendan seems
superior to dobutamine with regards to improving regional
and systemic perfusion, possibly because of its greater vasodilator effect. An RCT on 40 patients with septic shock
compared a 24 h infusion of levosimendan 0.2 μg/kg/min
vs. dobutamine 5 μg/kg/min: dobutamine was comparable to
levosimendan with regards to reduction of mean pulmonary
artery pressure, right atrial pressure and pulmonary artery
occlusion pressure, and increase of stroke index and cardiac
index (CI), but regional and systemic perfusion were significantly higher in the levosimendan group [40].
Unfortunately, it is not clear whether the observed hemodynamic advantages of levosimendan over dobutamine
result in improved survival. A secondary analysis of data
from the LIDO study showed that patients treated with levosimendan had higher 180-day survival. In contrast, the SUR-
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VIVE study, a large (1,327 patients) multi-center (75 centers) international (9 countries) RCT showed that all-cause
mortality at 6 months was 26% in the levosimendan group
vs. 28% in the dobutamine group, and the difference was not
significant [41]. In contrast, secondary analysis of the SURVIVE study data showed lower mortality with levosimendan
in patients with decompensated chronic heart failure and in
patients previously treated with beta-blockers [42]. However, levosimendan does not seem superior to dobutamine
with regards to survival in patients with acute heart failure
without history of chronic heart failure [43].
Levosimendan seems to have synergistic hemodynamic
effects with dobutamine. A prospective study evaluated the
effects of combining levosimendan with dobutamine on 18
patients hospitalized for NYHA class IV heart failure refractory to continuous 24-h infusion of dobutamine 10 μg/kg/
min and furosemide 10 mg/h. Addition of levosimendan (6
μg/kg bolus followed by infusion at 0.2 μg/kg/min for 24 h)
was well tolerated, increased CI by > 40% in 14 of 18 patients at the end of the combined infusion, and the observed
improvement of CI persisted 1 week later. This study concluded that the levosimendan/dobutamine combination was
more effective than dobutamine alone, without additional
adverse effects in refractory heart failure [44]. These results
suggest that levosimendan is probably not meant to replace
dobutamine, but is a useful adjunct therapy in patients with
heart failure refractory to dobutamine.
Levosimendan vs. phosphodiesterase inhibitors
Experimental data suggest that levosimendan and phosphodiesterase inhibitors have similar efficacy in improving systolic cardiac function [45] and may exert similar cardioprotective effects [46]. However, levosimendan also improves
diastolic cardiac function, whereas milrinone does not [46,
47].
An RCT on 30 patients with LVEF < 30% scheduled for
elective cardiac surgery compared milrinone 0.5 μg/kg/min
vs. levosimendan 0.1 μg/kg/min starting after the release of
the aortic cross-clamp, while all patients also received dobutamine 5 μg/kg/min. In this study, patients in the levosimendan group required lower doses of norepinephrine (P =
0.007) had faster weaning from dobutamine, shorter duration of mechanical ventilation (P = 0.008) and no differences
in adverse effects (hypotension, arrhythmia), ICU length of
stay (LOS) or hospital LOS. With regards to mortality, there
were three deaths in the milrinone vs. 0 deaths in the levosimendan group at 30 days, but this difference did not reach
statistical significance [48].
Another RCT compared levosimendan (bolus 12 μg/kg
over 10 min followed by infusion at 0.1 - 0.2 μg/kg/min for
24 h) vs. milrinone (bolus 50 μg/kg over 10 min followed
by infusion of 0.3 - 0.5 μg/kg/min for 24 h) on 30 patients
with type II diabetes and low LVEF who developed low car-
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diac output syndrome (LCOS) after cardiopulmonary bypass
(CPB) for elective coronary artery bypass graft (CABG) surgery. This study showed significantly higher CI (P = 0.01)
and mixed venous oxygen saturation (P < 0.001) and significantly lower oxygen extraction ratio (P = 0.03), pulmonary
capillary wedge pressure (PCWP) (P = 0.04) and systemic
vascular resistance (SVR) (P = 0.01) in the levosimendan
group compared to the milrinone group [49].
Levosimendan has also been compared to enoximone
in an RCT on 32 patients with persistent cardiogenic shock
(shock despite successful reperfusion therapy, administration of inotropes and fluids and support with intra-aortic
balloon pump (IABP)) after acute MI. Levosimendan was
given as 12 μg/kg over 10 min loading dose followed by 0.1
μg/kg/min infusion for 50 min and 0.2 μg/kg/min infusion
over 23 h, whereas enoximone was given as 0.5 μg/kg over
30 min bolus followed by 2 - 10 μg/kg/min infusion titrated
to hemodynamic response for a median of 5.1 days. In this
study, although hemodynamic changes did not differ significantly between the two groups, survival was higher in the
levosimendan group (69% with levosimendan vs. 37% with
enoximone, P = 0.023) [50].

Levosimendan in Critically Ill Patients
Levosimendan in cardiac surgery
Morbidity after cardiac surgery has increased in recent years
and, despite improved cardioplegic protection, postoperative
LCOS remains a problem, largely because cardiac surgery
is increasingly utilized in older, higher risk patients. LCOS
consists of transient ventricular dysfunction related to global
myocardial ischemia and reperfusion injury, is also known as
myocardial stunning and is associated with high morbidity
and mortality. In one meta-analysis, cardiac surgery patients
who received levosimendan perioperatively had lower mortality compared to patients treated with placebo, dobutamine
or milrinone (4.7% vs. 12.7%, P = 0.003), whereas another
meta-analysis included 139 cardiac surgery patients from
five RCTs and showed that levosimendan has cardioprotective effects, as evidenced by lower postoperative troponin
levels in patients receiving levosimendan. However, these
finding are based on relatively small number of patients, and
need to be confirmed in larger studies [51, 52].
One RCT evaluating levosimendan (10 μg/kg loading
dose followed by 0.1 μg/kg/min for 24 h) vs. dobutamine
(starting at 5 μg/kg/min) as monotherapy in 137 patients with
LCOS after elective CABG showed fewer complications and
significantly lower mortality (9% vs. 25%, P < 0.05) in the
levosimendan group [53].
Levosimendan for primary graft failure after heart transplantation has been reported in two publications originating
from the same center in Germany [54, 55]. Levosimendan
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was given as 24-h infusion at 0.1 μg/kg/min in 12 patients
with primary graft failure, resulted in rapid improvement of
heart function and 30 day survival was 92% [55].
Prophylactic levosimendan has also been evaluated in
cardiac surgery: an RCT evaluated levosimendan use (bolus
12 μg/kg followed by infusion at 0.2 μg/kg/min) immediately after induction of general anesthesia vs. placebo in 60
patients with LVEF < 50% undergoing CABG surgery, and
showed that a primary weaning from CPB was successful
in 22 patients (73%) in the levosimendan group vs. 10 patients (33%, P = 0.002) in the placebo group [56]. Another
prospective study in patients with LVEF < 35% undergoing
cardiac surgery under CPB compared prophylactic levosimendan (bolus 12 μg/kg followed by infusion at 0.1 μg/kg/
min for 24 h) starting after induction of anesthesia vs. IABP
starting 16 - 18 h before surgery, and showed higher CI and
lower troponin levels 6 h after surgery and significantly
shorter ICU LOS in the levosimendan group [57].
Similarly, another RCT on 252 patients with LVEF <
25% undergoing CABG under CPB, compared preoperative
levosimendan (loading dose 10 μg/kg followed by infusion
at 0.1 μg/kg/min for 23 h) vs. placebo and showed significantly lower incidence of LCOS (7.1% vs. 20.8%, P < 0.05),
lower requirement for IABP (6.3% vs. 30.4%, P < 0.05) and
lower mortality (3.9% vs. 12.8%, P < 0.05) in the levosimendan group [58]. Another small retrospective study compared
10 high-risk cardiac surgery patients (Euroscore > 6) with
severe left ventricle (LV) dysfunction who received prophylactic levosimendan (bolus 24 μg/kg followed by infusion
at 0.1 μg/kg/min for 24 h) with 12 historical controls and
showed that patients who received levosimendan had higher
CI, shorter hospital LOS and lower 30-day mortality compared to patients who received dobutamine and milrinone
[59].
Furthermore, an RCT on 106 patients undergoing elective CABG surgery evaluated levosimendan (24 μg/kg as
slow IV bolus 10 min before CPB) vs. placebo and showed
lower troponin values (P = 0.0001), reduced need for inotropic support and significantly shorter duration of mechanical ventilation and ICU LOS (P = 0.01) in the levosimendan
group [60].
However, a retrospective matched-control study in patients with LVEF < 30% undergoing cardiac surgery concluded that prophylactic levosimendan infusion starting before weaning from CPB resulted in significantly lower mean
arterial pressure and need for higher doses of norepinephrine, without any benefit in CI, mixed venous oxygen saturation, or 30-day mortality [61].
Although the inotropic and vasodilator effects of levosimendan are a concern in patients with severe valve disease,
particularly aortic stenosis [62], a recent report described
successful preoperative levosimendan use in two adults with
severe aortic stenosis [63], and a few studies have evaluated
the use of levosimendan in heart valve surgery. A small RCT
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from Finland on 24 patients undergoing aortic valve replacement with or without CABG showed that patients who received levosimendan at 0.2 μg/kg/min for 24 h starting after
induction of anesthesia required more norepinephrine during
surgery and less nitroprusside after surgery, but maintained
their pre-CPB LVEF and avoided myocardial stunning [64].
Similarly, a large RCT from a different center in Finland
evaluated levosimendan (24 μg/kg bolus over 30 min) starting immediately after induction of anesthesia and continuing
at 0.2 μg/kg/min for 24 h vs. placebo in 200 patients with
normal preoperative cardiac function undergoing elective
isolated valve or combined valve-CABG surgery [65]. This
study showed reduced heart failure but increased need for
vasopressors and no difference in 6-month mortality in the
levosimendan group.
In conclusion, the optimal strategy for levosimendan
administration (prophylactic vs. use in LCOS) in cardiac
surgery is matter of discussion [66]. Early levosimendan administration may be more effective [67], but the issue has not
been resolved and deserves further evaluation.
Levosimendan in cardiogenic shock
Because levosimendan causes vasodilation, cardiogenic
shock has been exclusion criterion in studies evaluating levosimendan safety, and therefore levosimendan has not been
adequately studied in cardiogenic shock. In the BELIEF
study, hypotension (SBP < 90 mmHg) before levosimendan
administration was a good predictor for absence of response
to levosimendan treatment [34]. However, published data
suggest that levosimendan is well tolerated in patients with
cardiogenic shock after acute MI [68, 69] and its hemodynamic effects are comparable to those of IABP [70], but the
timing of levosimendan administration remains matter of
controversy. One prospective observational study compared
early (in the cardiac catheterization suite at the time of IABP
initiation) vs. late (persistent cardiogenic shock despite successful reperfusion therapy, IABP and optimized fluid administration) levosimendan administration and showed no
benefit in short term (< 30 days) or long term (> 30 days)
mortality with early levosimendan administration [71]. Late
levosimendan administration significantly increased CI
without hemodynamic deterioration in patients with persistent cardiogenic shock (no improvement of CI after reperfusion treatment, IABP, optimized fluid or dobutamine administration) [72, 73], but hemodynamic improvement did
not improve survival [72]. To this day, there are no RCTs
evaluating levosimendan in cardiogenic shock secondary to
acute MI.
Experimental data in dogs show that levosimendan improves right ventricular function in load-induced acute right
ventricular failure [74]. Three studies evaluating levosimendan in cardiogenic shock due to bi-ventricular acute heart
failure showed improved right ventricular function [75-77],

80

presumably due to decreased pulmonary vascular resistance
and improved right ventricular systolic function. Furthermore, the observed improvement of right ventricular systolic
function (as measured with right ventricular cardiac power
index (CPI)) was related to survival [77]. To this date, there
are no studies evaluating levosimendan in cardiogenic shock
secondary to isolated right heart failure.
Levosimendan could potentially be effective in other
types of cardiogenic shock, such as in fulminant myocarditis
[78], in patients with takotsubo cardiomyopathy [79, 80] and
in cardiomyopathy after cardiac arrest, but there are no prospective clinical trials evaluating the role of levosimendan in
these settings.
Levosimendan in sepsis
Sepsis and septic shock have complex pathophysiology, including cardiovascular dysfunction characterized by signs of
distributive shock and of septic cardiomyopathy consisting
of bi-ventricular myocardial contractility impairment and diastolic dysfunction. Available evidence suggests that cardiac
failure in septic shock is not always corrected by vasoactive
and inotropic agents or fluid therapy [81].
Experimental studies show that levosimendan improves
systolic and diastolic myocardial function in sepsis, whereas
clinical studies have shown that levosimendan improves cardiac function in patients with septic shock. Consequently, levosimendan could be a valuable adjunct (or replacement) in
the treatment of sepsis-related myocardial dysfunction with
catecholamines, but there are no guidelines for levosimendan use in sepsis. A pilot RCT on 35 patients with septic
shock and acute respiratory distress syndrome (ARDS), but
without signs of right heart failure showed that continuous
infusion of levosimendan (0.2 μg/kg/min for 24 h) decreased
pulmonary resistance and improved right ventricular function (decreased telosystolic volume, increased EF) compared
to placebo [82]. Yet, it is unclear whether the observed improvement of right ventricular function and reduction of
pulmonary vascular resistance is due to direct levosimendan
effect on the right ventricle or to improved LV function.
Levosimendan could also be effective in patients with
sepsis-related myocardial dysfunction who do not respond
to dobutamine: an RCT on 28 patients with septic shock and
left ventricular dysfunction showed hemodynamic improvement with levosimendan (0.2 μg/kg/min) even in patients
who had not responded to dobutamine [83]. These results
suggest that levosimendan could be an alternative option in
cases where dobutamine is not effective, but this possible use
needs further evaluation.
Levosimendan in renal dysfunction and renal failure
The long-term impact of levosimendan on renal function has
not been well defined. An RCT on 40 patients with advanced
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chronic heart failure listed for heart transplantation evaluated the effect of levosimendan on renal function, and showed
that patients receiving levosimendan had lower serum creatinine and higher creatinine clearance 3 months after levosimendan administration [84]. Other reports also suggest that
levosimendan can have beneficial effects with regards to renal function. An RCT by Bragadottir [85] compared postoperative infusion of levosimendan (loading 12 μg/kg followed
by infusion at 0.1 μg/kg/min) vs. placebo in the cardiothoracic ICU on 30 patients who had cardiac surgery. In this
study, levosimendan increased renal blood flow by 12% (P <
0.05) and glomerular filtration rate by 21% (P < 0.05). Similarly, an RCT by Hou et al compared a 24-h infusion of levosimendan vs. placebo in 66 patients with LVEF < 40% and
DHF, and showed that levosimendan transiently improved
renal dysfunction, and this improvement persisted for at least
14 days [86]. A study by Yilmaz showed that, compared to
dobutamine, levosimendan resulted in improved renal function in heart failure patients requiring inotropic therapy [76],
and a case report of a 14-year-old patient suggested that levosimendan is useful in cases of resistant acute heart failure
with arterial hypertension and ESRD [87]. However, it is important to remember that levosimendan doses should be reduced when used for congestive heart failure in patients with
severe renal insufficiency [30]. A recent consensus statement
by 25 scientists from 15 European countries acknowledged
that most reports on levosimendan use show improvement of
renal function in heart failure, sepsis and cardiac surgery, but
also voiced caution with interpretation of these findings due
to variability in study design, and also because the largest
heart failure study (REVIVE I and II) did not show improved
renal function [88]. Clearly, although available data suggest
that levosimendan can be useful in patients with renal dysfunction and heart failure, the role of levosimendan in this
patient population needs further study.

Conclusion
Levosimendan is a positive inotropic agent with many potential applications in critically ill patients. However, indications, contraindications and optimal use of levosimendan in
the ICU have not been adequately evaluated. Although one
meta-analysis and several clinical studies report positive results with use of levosimendan in critically ill patients, we
believe that currently available evidence cannot support safe
conclusions regarding the role of levosimendan in the ICU,
and data from large, well-designed RCTs are needed to validate these preliminary results.
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